Besides the well-known role of ABC-transporters in the efflux of the conventional anticancer agents from tumor cells, the emerging number of evidence demonstrates that MDR might also affect the anti-cancer activities of the tyrosine kinase inhibitors (TKIs). This evidence concerns the gene ABCG2 and neoplasm.